InBrain Neuroelectronics has partnered with Microsoft to explore how it can advance precision neurology by applying agentic AI to its brain computer-interface (BCI) platform.
The strategic partnership will give the Spanish company access to Microsoft Azure, a cloud-based platform that includes large language models (LLMs) and related data analytics capabilities that facilitate the deployment of agentic AI.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Viewed as the next evolution of AI, agentic AI allows for systems that apply the technology to act autonomously on the basis of real time data.
According to GlobalData analysis, the overall application of AI across healthcare will reach a valuation of $19bn by 2027.
InBrain’s lead product is a BCI platform made of graphene arranged in a hexagonal lattice that provides adaptive neuromodulation for conditions such as Parkinson’s disease and epilepsy. The company aims to apply agentic AI to the BCI so it is able to continuously learn and adapt to individual patient signals.
According to InBrain, agentic AI has the potential to transform how neurological disorders are monitored and treated. By integrating advanced decoding and modulation with agentic AI, InBrain said its aim is to develop a new class of AI-enabled BCI therapeutics that are capable of delivering personalised, real time neural circuitry modulation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataInBrain’s CEO Carolina Aguilar said: “Our vision is to create the most intelligent, autonomous, and personalised interface between the nervous system and AI.
“By collaborating with Microsoft, we’re combining our precision graphene neural technology with one of the world’s most powerful AI ecosystems. This partnership brings us closer to a future where brain-computer interfaces don’t just decode or modulate but truly understand and respond to the nervous system in real time.”
Agentic AI is showing signs of growth across various healthcare domains, with rising use cases in areas such as advancing cancer diagnostics and in assisting clinicians with documentation and workflow tasks.
A recent report by KPMG found that agentic AI was the third top applicational form of AI currently being adopted in healthcare, behind generative AI and speech recognition in first and second place, respectively.
However, as the tech advances, experts foresee new legal challenges arising, particularly around distinguishing between medical devices and hardware, AI software, and human healthcare providers when apportioning negligence.
